// App-Quantinova.ai

1797 : BAY 94-9027 Provides Safe and Effective Long-Term Prophylaxis in Pediatric Patients: Results from the PROTECT VIII Kids Extension Study

Researchers

Presenter

  • Sanjay Ahuja

Principal Investigators

  • Kathelijn Fischer

  • Tina Biss

  • Monika Maas Enriquez

  • Maria-Elisa Mancuso

  • MacGregor Steele

  • Maria Wang

  • Gili Kenet

Medical Centers

  • Case Western Reserve University, Cleveland, OH

  • Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands

  • Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom

  • Bayer Pharma AG, Berlin, Germany

  • Center for Thrombosis and Hemorrhagic Diseases, Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy

  • Cumming School of Medicine, Alberta Children’s Hospital, University of Calgary, Calgary, Canada

  • Bayer AG, Whippany, NJ

  • Israel National Hemophilia Center and Thrombosis Unit, Chaim Sheba Medical Centre, Tel‐Hashomer, Israel

Locations

  • United States

  • Netherlands

  • United Kingdom

  • Germany

  • Italy

  • Canada

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Acute renal failure

  • Hemophilia

  • Albuminuria

  • Trauma

Biomarkers

  • Cystatin C

  • Lipocalin 2

Drug/Treatment

  • Recombinant Factor VIII

  • damoctocog alfa pegol

  • BAY 94-9027

  • FVIII

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Expansion Study

Phase

  • NA

Study Id's

  • NCT01775618

Sponsors

  • Bayer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved